Home
HomeChat
Markets
AlertsCalendarScreenerCharts
Portfolio
WatchlistsPortfolioFiles
Account
Docs
Sign upJoinLog inLogin

Rafael Holdings, Inc. (RFL) stock profile

Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments: Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage, and the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.

Key facts

SymbolRFL
ExchangeNYSE
SectorReal Estate
IndustryReal Estate - Services
CEOHoward S. Jonas
Employees28
HeadquartersNewark, NJ, US
IPO2018-03-27
Websitewww.rafaelholdings.com

Explore RFL on Vantafin

  • Rafael Holdings, Inc. Overview
  • Rafael Holdings, Inc. Financials
  • Rafael Holdings, Inc. News
  • Rafael Holdings, Inc. Events
  • Rafael Holdings, Inc. SEC filings
  • Rafael Holdings, Inc. Insider transactions

Frequently asked questions

What does Rafael Holdings, Inc. (RFL) do?
Rafael Holdings, Inc. holds interests in clinical and early stage pharmaceutical companies, and commercial real estate assets in the United States and Israel. The company operates in two segments: Pharmaceuticals and Real Estate. It engages in the leasing of a commercial office building, as well as an associated 800-car public garage, and the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. The company's lead drug candidate is CPI-613 (devimistat), which is being evaluated in various clinical studies, including two Phase III registrational clinical trials for the treatment of metastatic pancreatic cancer and r/r acute myeloid leukemia. Rafael Holdings, Inc. is headquartered in Newark, New Jersey.
Where is RFL stock listed?
Rafael Holdings, Inc. trades under the ticker RFL on NYSE.
How can I research RFL's financials and filings?
Vantafin provides Rafael Holdings, Inc.'s income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the RFL profile.